Prognostic factors in patients with clinic locally advanced T4 lung cancer: surgical considerations

Basit Öğe Kaydı
dc.authoridTuğba Coşgun / 0000-0002-4407-519Xen_US
dc.authorscopusidTuğba Coşgun / 55255764900
dc.authorwosidTuğba Coşgun / ERD-3295-2022en_US
dc.contributor.authorKaba, Erkan
dc.contributor.authorCoşgun, Tuğba
dc.contributor.authorYardımcı, Halit
dc.contributor.authorToker, Alper
dc.date.accessioned2023-01-26T12:44:36Z
dc.date.available2023-01-26T12:44:36Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground Inclusion of surgery in the treatment of T4 lung cancer has been a debate for the last two decades. The aim of this study is to investigate the potential prognostic factors which could affect the outcome.Methods Fifty-seven clinical T4 non-small cell lung carcinoma (NSCLC) patients out of 716 lung resections, who were operated at a single institution in 7 years period, were included in this study. Patients are grouped into three groups as patients with neoadjuvant treatment group (group 1 n : 16), salvage surgery group (surgery after 3 months of definitive chemotherapy and radiotherapy) (group 2 n : 14), and straightforward surgery group (group 3 n : 27) with adjuvant treatment. Groups were analyzed and compared in terms of postoperative complications, 30 days of mortality, disease free survival, and overall survival.Results Mean overall survival (OS) was 48.43 +/- 4.4 months and mean disease-free survival (DFS) 40.55 +/- 4.46 months for all patients. Thirty days mortality was 5.2% and complication rates were 63.1%. Two years OS was 61.4 +/- 6.4%, DFS was 58.1 +/- 7.8%. Group 1, Group 2, and Group 3 patients had mean 39.14 +/- 5.6, 44.7 +/- 7.1, and 62.9 +/- 4.8 months for OS ( p : 0.09), and 29.6 +/- 7.2, 38.4 +/- 9.1, and 46.9 +/- 6 months for DFS ( p : 0.27). Patients who received blood transfusion showed significantly worse outcomes ( p : 0.001 for DFS and p : 0.004 for OS).Conclusion According to our outcomes, surgery should be included in the treatment of clinical T4 lung cancer when physiologically and oncologically possible with careful patient selection. This study demonstrates that patients receiving straightforward surgery have longer survival, in spite of higher perioperative mortality rate. Risks and benefits should be considered carefully.en_US
dc.identifier.citationKaba, E., Cosgun, T., Yardimci, H., & Toker, A. (2022). Prognostic Factors in Patients with Clinic Locally Advanced T4 Lung Cancer: Surgical Considerations. The Thoracic and Cardiovascular Surgeon.en_US
dc.identifier.doi10.1055/s-0042-1759722en_US
dc.identifier.issn0171-6425en_US
dc.identifier.issn1439-1902en_US
dc.identifier.urihttp://dx.doi.org/10.1055/s-0042-1759722
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3845
dc.identifier.wosWOS:000900753000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorCoşgun, Tuğba
dc.language.isoenen_US
dc.publisherGEORG THIEME VERLAG KGen_US
dc.relation.ispartofTHORACIC AND CARDIOVASCULAR SURGEONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectTNM Stagingen_US
dc.subjectT4 Tumoren_US
dc.titlePrognostic factors in patients with clinic locally advanced T4 lung cancer: surgical considerationsen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu